In-house members
11
Total footprint
15,000 sq ft
The incubator where it all started, our St Philips incubator is typically home to earlier-stage Deep Tech teams of around 10-20 and has been the launchpad for many success stories — from startups scaling to bigger facilities to game-changing company exits.
Work alongside pioneering startups tackling global issues — from next-generation battery materials and better diabetes treatments to quantum-enabled cameras to track greenhouse gas leaks.
Our St Philips incubator (previously Unit DX) opened in 2017 to improve access to lab space and facilities for scientific companies in Bristol.
Just a 10-minute walk from Bristol Temple Meads train station, the space combines purpose-built laboratories, flexible offices and cutting-edge instrumentation.
Rent an entire lab or just a lab bench; have a private office or share one — and access our platform of support, providing opportunities to attend workshops and events, connect with other founders, and find a mentor.
Get in touch if you are after shared lab space at St Philips or browse our other sites if you are looking for private lab space.
Travel between locations is measured in walking distance
Albert Rd
0.5 miles / 11 min
0.7 miles / 15 min
neo-fossil is developing new technology using cell engineering to help reverse the threat of climate change. By optimising biology, it is creating new fossils that harvest atmospheric carbon dioxide, storing it for centuries.
Kelpi is tackling plastic pollution by developing sustainable alternatives to single-use plastic packaging. It uses seaweed to create a unique bioplastic coating that provides a world-leading water barrier for new-generation packaging while being recyclable, biodegradable, and low carbon. By working with major food and drink, cosmetics and home care brands, Kelpi is already reducing reliance on fossil-fuel plastics and paving the way for a greener future in these industries.
GenomeKey is transforming how healthcare clinicians diagnose and treat infections like sepsis to improve patient outcomes. Using cutting-edge machine learning and DNA sequencing, the company is developing a next-generation diagnostic device to identify bacterial genomes and determine their antimicrobial susceptibility directly from patient blood in just a few hours, rather than days. This enables clinicians to prescribe the right antibiotics for patients with much more efficiency and accuracy, reducing costs, minimising unnecessary antibiotic use and ultimately saving millions of lives from the world’s leading cause of death.
Lifecare is committed to improving the lives of people and pets with diabetes. It is developing the next-generation of miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers to the market. The company’s spin-off entity Lifecare Chemistry Ltd was founded to enhance research collaboration and secure ownership of its improved analyte-specific chemical receptor developments.
Invivo Healthcare is developing solutions to better understand and modulate human microbiomes, promoting long-term wellness and a sustainable future of healthcare. Its supplement therapeutics are plant, nutrient and microorganism-based, designed to lead the way in combating the rise of chronic diseases and a reductionist approach to medicine.
Argonaute RNA is developing safe, reliable and targeted methods of temporarily silencing genes in different tissue cells. It does this via the proprietary modification of small interfering RNA (siRNA), using a novel stabilisation method to overcome previous obstacles to developing siRNA drugs for healthcare.
Reach Industries is optimising lab and scientist efficiency with its Lumi™ visual intelligence platform. By automating data capture and analysis for experiments, observations and complex scientific workflows, the platform functions as a streamlined operating system that is accelerating R&D, improving compliance and increasing reproducibility.
Extracellular is developing cell culture technologies to use the cell samples of living animals and plants to create sustainable alternatives to commercial products in the cosmetic, material and food industries. As a bioprocessing and manufacturing partner, it provides solutions from cell-line and scale-up development to facilitating routes to market, supporting other biotech companies seeking to develop greener consumer products such as cultivated meat, dairy products, leather, cotton and active ingredients for cosmetics.
CellVoyant is accelerating the development of novel stem cell-based therapies for chronic diseases. Its technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, enable advanced cell analytics and ultimately unlock the controllable manufacturing of any cell and tissue in the body at scale. Built on foundational research at the University of Bristol, CellVoyant works at the intersection of cell biology, computing, engineering and machine learning to carry out its mission.